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Introduction: Community-acquired pneumonia (CAP) requires prompt treatment, but its diagnosis is complex.
Improvement of bacterial CAP diagnosis by biomarkers has been evaluated using chest X-ray infiltrate as the CAP
gold standard, producing conflicting results. We analyzed the diagnostic accuracy of biomarkers in suspected CAP
adults visiting emergency departments for whom CAP diagnosis was established by an adjudication committee
which founded its judgment on a systematic multidetector thoracic CT scan.
Methods: In an ancillary study of a multi-center prospective study evaluating the impact of systematic thoracic CT
scan on CAP diagnosis, sensitivity and specificity of C-reactive protein (CRP) and procalcitonin (PCT) were evaluated.
Systematic nasopharyngeal multiplex respiratory virus PCR was performed at inclusion. An adjudication committee
classified CAP diagnostic probability on a 4-level Likert scale, based on all available data.
Results: Two hundred patients with suspected CAP were analyzed. The adjudication committee classified 98 patients
(49.0 %) as definite CAP, 8 (4.0 %) as probable, 23 (11.5 %) as possible and excluded in 71 (35.5 %, including 29 patients
with pulmonary infiltrates on chest X-ray). Among patients with radiological pulmonary infiltrate, 23 % were finally
classified as excluded. Viruses were identified by PCR in 29 % of patients classified as definite. Area under the curve was
0.787 [95 % confidence interval (95 % CI), 0.717 to 0.857] for CRP and 0.655 (95 % CI, 0.570 to 0.739) for PCT to detect
definite CAP. CRP threshold at 50 mg/L resulted in a positive predictive value of 0.76 and a negative predictive value of
0.75. No PCT cut-off resulted in satisfactory positive or negative predictive values. CRP and PCT accuracy was not
improved by exclusion of the 25 (25.5 %) definite viral CAP cases.
Conclusions: For patients with suspected CAP visiting emergency departments, diagnostic accuracy of CRP and PCT
are insufficient to confirm the CAP diagnosis established using a gold standard that includes thoracic CT scan.
Diagnostic accuracy of these biomarkers is also insufficient to distinguish bacterial CAP from viral CAP.
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Community-acquired pneumonia (CAP) is a frequently
seen disease, with high morbidity and mortality,
accounting for 600,000 hospitalizations each year. It
represents the seventh leading cause of death in the
USA [1]. CAP prognosis depends on the rapidity of
specific treatment, which should ideally be initiated
within four hours and no later than eight hours after
diagnosis [2, 3]. CAP diagnosis is based on the clus-
tering of non-specific pulmonary and general symp-
toms [4, 5], an increase in biomarkers reflecting
systemic inflammatory response syndrome (SIRS), and
the presence of new parenchymal infiltrates on chest
X-ray. However, CAP diagnosis remains uncertain in
many cases with alternative diagnoses, such as cardiac
failure, acute bronchitis, chronic obstructive pulmonary
disease (COPD) exacerbations, pulmonary embolism,
neoplasia, and sepsis [6, 7].
Part of the uncertainty of CAP diagnosis may be due
to the high rate of chest X-ray misdiagnosis [8, 9]; over
diagnosis of CAP is frequent when infiltrates of non-
infectious origin coexist with pulmonary or general
symptoms, and the diagnosis of CAP is often ignored
when the lung infiltrates are at the limit of visibility or
are hidden due to superposition [10]. We recently
published a study in which thoracic CT scan was
systematically performed in a population of clinically
suspected CAP patients visiting the emergency
department for CAP (the ESCAPED study) [11]. We
showed that CAP diagnosis based on chest X-ray led
to a false CAP diagnosis in many patients: among
CAP suspected patients with radiological pulmonary
infiltrate, CAP diagnosis was excluded in around
30 % of patients based on CT scan results; on the
contrary, among patients without radiological pulmonary
infiltrate, one-third had a pulmonary infiltrate on thoracic
CT-scan. We also reported the isolation of viruses in
one-third of patients [11, 12].
Several attempts have been made to improve CAP
diagnosis based on biomarkers, such as C-reactive pro-
tein (CRP) and procalcitonin (PCT); however, there are
conflicting data on their reliability [13–17]. This could
be due to the consideration of CAP diagnosis based on
chest X-ray as establishing pulmonary infection. In the
present study, we aimed to analyze CRP and PCT values
in the population of the ESCAPED study reported above
for whom CAP diagnosis was established by an adjudica-
tion committee which founded its judgment on all usual
available data, systematic multidetector thoracic CT scan
performed at inclusion, and results from a day-28
follow-up. We also analyzed whether the viral etiology
of definite CAP based on polymerase chain reaction
(PCR) multiplex naso-pharyngeal swab interfered with
the accuracy of the biomarkers.Methods
Setting
ESCAPED was a multicenter, prospective, interventional
study, entitled “Early Thoracic CT-Scan for Community-
Acquired Pneumonia at the Emergency Department
(ESCAPED)” [11], conducted from November 2011 to
January 2013, in four emergency departments (EDs)
of four tertiary teaching hospitals in Paris, France,
designed to measure the impact of thoracic CT scan
on clinical decision. The study was sponsored and
monitored by the Paris public health hospitals, and
funded by the French Ministry of Health. The French
health authorities (Agence nationale de sécurité des
medicaments et produits de santé, ANSM) and the
institutional review board for the protection of human
subjects approved the study protocol and patient informed
consent procedures. All enrolled patients provided written
informed consent for inclusion. The protocol was regis-
tered in the clinicaltrial.gov website under the PACSCAN
acronym, the French translation of the English ESCAPED
acronym (NCT01574066). The Ethics Committee of Ile de
France (Comité de Protection des Personnes. Paris N°
2011-oct-12749) approved the study protocol.
Objectives
The primary objective was to compare CRP and PCT
values in the four different categories of CAP level of
certainty using the day-28 adjudication committee classi-
fication. The four categories were: 1) absence of CAP
hereafter referred to as excluded CAP diagnosis; 2) pos-
sible CAP; 3) probable CAP; and 4) definite CAP. The
secondary objectives were to assess whether CRP and
PCT were associated with CAP diagnosis using sensitiv-
ity analyses in three successive subgroups chosen a
priori; 1) when specifically considering patients classified
as having excluded CAP diagnosis and definite CAP
(i.e., the patients for whom the level of certainty was
the highest); 2) when patients with excluded CAP
diagnosis and diagnosed extra-pulmonary infectious
disease (which may increase biomarker values) were
not taken into account, in the excluded CAP group;
and 3) when patients classified as viral CAP were not
taken into account in the definite CAP group, as
PCT has been reported to be lower in viral infections
as compared to bacterial infections [18].
Study population
Consecutive adults (18 years of age and above) visiting
the participating EDs were enrolled if the attending
emergency physician clinically suspected CAP. Clinical
suspicion of CAP was based on the investigator’s own
judgment and had to fulfill the following criteria: new
onset of systemic features (at least one among: sweat,
chills, aches and pain, temperature ≥38 °C or <36 °C)
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(at least one among: cough, sputum production, dyspnea,
chest pain, altered breathing sounds at auscultation).
Pregnant women, patients in palliative care or with
anticipated barriers to completing follow-up data collec-
tion, patients classified ≥3 according to the CRB65 score
and those requiring intensive care for any purpose, due to
specific management of critically ill CAP patients, were not
eligible. This study examined patients from the ESCAPED
study, for whom the CRP and PCT values and the multi-
plex PCR results were all available.
Patient management and data collection
Patient management was based on local practices in the
emergency departments. No recommendation was given
concerning the performance of CRP and PCT dosage, as
no dosages are recommended in French CAP guidelines.
Recorded baseline data consisted of demographic data
(age, gender), coexisting illnesses, symptoms, clinical
findings and laboratory tests. For each individual, CRB65
and Pneumonia Severity Index (PSI) were calculated [19].
Radiological data and CAP diagnosis classification
Multidetector thoracic CT-scan was performed after
chest X-ray, ideally within the four hours following
inclusion. Chest X-ray and thoracic CT-scan were
performed using a standardized protocol. The four levels
of CAP probability according to CT scan were defined
as definite (systematic alveolar condensation, alveolar
condensation with peripheral and localized ground glass
opacities, bronchiolar focal or multifocal micronodules),
probable (peripheral alveolar condensation, retractile
systematic alveolar condensation, or diffuse ground glass
opacities), possible (pulmonary infarct), or excluded
(pulmonary mass, other abnormalities, or normal images).
Scan views were recorded on a DVD.
Adjudication committee
Based on data collected from baseline standardized case
report forms, DVD recorded pictures of X-ray and CT-
scan, and blinded to local interpretations, an adjudica-
tion committee consisting of three independent senior
experts in infectious diseases, pneumology and radiology
retrospectively assigned the probability of CAP diagnosis
using the same 4-level Likert scale, with all available
data including patients’ discharge summary, and
follow-up data obtained by assistant investigators who
contacted by phone either the patient, relatives or
general practitioners at day 28. For this study, the
gold standard of CAP was the diagnosis assessed by
this adjudication committee. Alternative diagnoses
were established for excluded CAP and classified as
non-CAP pulmonary diseases and extra-pulmonary
infectious diseases and others.Biomarker measurements
Blood samples were collected at inclusion in sodium
heparin-treated tubes, centrifuged, and stored at −40 °C
until completion of the study. CRP and PCT concentra-
tions were measured a posteriori on plasma collection
(see Additional file 1 for methodology), except for
patients in whom marker dosage was performed by the
emergency practitioner on his own initiative.
Microbiological samples and microbial CAP classification
Naso-pharyngeal swabs were collected at enrollment and
placed in a Middle Virocult MWE (Sigma®) transport
medium. Samples were kept at room temperature and
sent to the virology laboratory of Bichat - Claude Bernard
Hospital (Paris) as soon as possible after collection.
The samples were not frozen and thawed. Multiplex
PCR (RespiFinder-19 assay (Pathofinder®, Maastricht,
Netherlands)) was performed on naso-pharyngeal
swabs to detect 15 respiratory viruses - coronavirus
229E, NL63, OC43, human metapneumovirus (hMPV),
influenza A, A (H1N1) pdm2009 and B viruses, para-
influenza viruses 1, 2, 3, and 4, respiratory syncytial
virus (RSV) A and B, rhinovirus, adenovirus, and 4
intracellular bacteria - Bordetella pertussis, Chlamydo-
phila pneumoniae, Legionella pneumophila, Mycoplasma
pneumoniae, in one reaction. The multiplex PCR results
were not available to the adjudication committee. Routine
microbiological examinations were also performed at the
discretion of the emergency physicians and included blood
culture, sputum culture, and antigenuria (see Additional
file 1 for methodology).
CAP, classified as definite, was considered as being of
viral origin when multiplex PCR was positive for at least
one of the 15 respiratory viruses and no bacteria were
found using PCR and routine bacterial microbiological
samples (sputum, blood culture, antigenuria) when
performed.
Statistical analysis
Baseline and follow-up characteristics were described by
means and standard deviations (SD) or by median and
interquartile range (IQR) for continuous variables nor-
mally distributed or with skewed distribution, respectively,
and by percentages for categorical variables, for the total
study population and for the study groups. We performed
chi-square or Fisher exact tests when appropriate for
qualitative variables, and the Student or Mann–Whitney
tests for continuous variables with skewed distributions
to compare baseline patient characteristics and study
outcomes between study groups.
The distribution values of the biomarkers were
determined in the different populations of patients
using boxplots. The performances of CRP and PCT in
predicting definite CAP were evaluated by sensitivity
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evaluated at several cut-off points of 20 mg/L,
30 mg/L, 50 mg/L, 70 mg/L, and 100 mg/L, values
used in previous studies [15, 20, 21]. Several cut-off
points for PCT were chosen at the level of 0.10 μg/L
[18], and at the two levels for suspected bacterial
infection as stated by the manufacturer, i.e., 0.25 μg/L
and 0.50 μg/L. Sensitivities, specificities, positive predict-
ive values (PPVs), negative predictive values (NPVs), and
likelihood ratio were calculated. Receiver operating char-
acteristic (ROC) curves were drawn, area under the curve
AUC was computed and optimal cut-off was identified by
the maximization of the Youden’s index, comparing bio-
marker values in patients with excluded CAP and definite
CAP. From these optimal cut-offs for CRP and PCT, sen-
sitivity analyses were performed combining the CRP and
PCT cut-offs.
A multivariate logistic regression model was built to
identify factors associated with having definite CAP as
compared to having an excluded CAP diagnosis. We
excluded from the excluded CAP diagnosis group,
patients with an extra-pulmonary infectious disease. All
variables with a p value of < 0.25 in the bivariate analysis
were entered into a multivariate logistic regression withFig. 1 Flow chart of the studied population according to the day 28 adjud
CRP C-reactive protein, PCT procalcitonina backward stepwise approach; the discrimination was
evaluated by the C-index and its 95 % confidence interval
(95 % CI) and the calibration was evaluated by the
Hosmer Lemeshow goodness-of-fit test.
All tests were two-sided, and p-values below 0.05 were
considered to denote statistical significance. All statistical
analyses were performed using SPSS statistical software
version 21.0 (SPSS Inc., Chicago, IL, USA).
Results
Two hundred patients with suspected CAP out of the
319 in the ESCAPED study were included in the present
study, for which CRP and PCT assays and nasopharyn-
geal swab for multiplex PCR were available (Fig. 1).
Characteristics of the 200 patients (age, age more than
65, gender, probability of CAP diagnosis by adjudication
committee) were not significantly different from those of
the 119 other patients of the ESCAPED study and are
summarized in Table 1. CRP and PCT assays were
performed based on the emergency practitioner’s own
initiative in 70 patients for CRP and 131 for PCT, or per-
formed a posteriori on plasma samples of the remaining
patients. Sex ratio was approximately 1. More than half
of the patients (54 %) were 65 years of age or older. Theication committee classification CAP community-acquired pneumonia,
Table 1 Characteristics of the 200 patients of the study
No (%) or mean ± SDa
Characteristics Total (n = 200)
General characteristics
Age
Mean age (years) 63.9 ± 19.1




Nursing home resident 8 (4.0)
Background and vaccinations
Comorbidities
At least 1 comorbidity 102 (51.0)
Chronic respiratory disease 57 (28.5)
Congestive heart failure 16 (8.0)
Kidney disease 13 (6.5)
Neoplasia 18 (9.0)
Liver disease 9 (4.5)
History of stroke 7 (3.5)
Vaccination status
Influenza vaccination during the past year 75 (37.5)
Pneumococcal vaccination 27 (13.5)
Community-acquired pneumonia characteristics
at inclusion
Previous antibiotic treatment 68 (34.0)
Symptoms duration before visiting ED (days) 9.6 ± 10.9
Signs and symptoms in the ED
Cough 153 (76.5)









Respiratory rate > 30/min 24 (12.0)
Heart rate > 125/min 13 (6.5)
Systolic blood pressure < 90 mmHg 4 (2.0)












White blood cell (103/mm3) 11.6 ± 5.0
Urea > 11 mmol/L 23 (11.5)
pH < 7.35 2 (1.0)
PaO2 < 60 mmHg or Sat02 < 90 % 25 (12.5)
Biomarkers resultsa
CRP (mg/L)
In all patients (n = 200) 74.5 [21.6 - 150.8]
In patients with a CAP classified as
« excluded » (n = 71) 23.4 [5.0 - 96.2]
« possible » (n = 23) 48.6 [16.0 - 147.1]
« probable » (n = 8) 78.8 [27.7 - 240.9]
« definite » (n = 98) 125.1 [65.0 - 208.7]
Procalcitonin (PCT) (μg/L)
In all patients (n = 200) 0.18 [0.07 - 0.91]
In patients with a CAP classified
« excluded » (n = 71) 0.11 [0.06 - 0.42]
« possible » (n = 23) 0.14 [0.07 - 0.63]
« probable » (n = 8) 0.63 [0.06 - 1.41]
« definite » (n = 98) 0.24 [0.11 - 1.38]
Community-acquired pneumonia management
Emergency physician's mean years in practice 5.8 ± 6.0
28-day mortality 6 (3.0)
Abbreviations: ED emergency department, PSI Pneumonia Severity Index, CRP
C-reactive protein, CAP community-acquired pneumonia
aResults are expressed as number (%) or mean ± standard deviation (SD)
except for biomarker results expressed as median (IQR)
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disorders was 102 (51 %), including 57 (28 %) with
pulmonary disorders. Cough (n = 153, 76 %) and dyspnea
(n = 142, 71 %) were the most frequent symptoms.
Pulmonary auscultation detected unilateral crackles in 65
(32 %), and 96 (48 %) patients had expectoration.
Chest X-ray results and CT scan results
Pulmonary infiltrates were seen on chest X-ray in 127
(63.5 %) patients. Thoracic CT-scan excluded a CAP
diagnosis in 16.5 % of these 127 patients; on the contrary,
thoracic CT-scan revealed a parenchymal infiltrate in
27 % of the 73 patients without infiltrate on chest X-ray.
Day-28 adjudication committee classification
Based on all available data including multidetector CT
scan results (but excluding PCR results), the adjudication
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possible in 23 (11.5 %), probable in 8 (4.0 %), and definite
in 98 patients (49 %). Among the 71 excluded CAP
diagnoses, 59 were categorized as non-CAP pulmonary
diseases (neoplasia, acute bronchitis, emphysema, COPD,
pulmonary embolism, acute pulmonary edema, tubercu-
losis, miscellaneous) and 12 as extra-pulmonary infectious
diseases (urinary tract infections, septicemia, discitis, men-
ingitis, erysipela, acute sinusitis infection and peritonitis).
Bacterial and viral data of patients with a definite CAP
classification are presented in Additional file 2.
Biomarker results
The CRP and PCT distributions in the 200 patients are
presented in Fig. 2 according to the adjudication com-
mittee CAP classification. The median CRP value in-
creased progressively from 23.4 mg/L [5.0 – 96.2
(excluded CAP)] to 125.1 mg/L [65.0–208.7 (definite
CAP)] (p < 0.01), as did median PCT values [from
0.11 μg/L (0.06 – 0.42) to 0.24 μg/L (0.11 – 1.38),
respectively; p < 0.01].
A statistically significant difference between the two
groups (excluded CAP vs definite CAP) was demon-
strated for several cut-off points for CRP and PCT
(Table 2). For CRP, the value of 50 mg/L resulted in a
PPV of 0.76 and a NPV of 0.75. For PCT, no value
resulted in a satisfactory PPV or NPV. For these two
biochemical markers, the ability to predict CAP was
evaluated by a ROC curve. The AUC was 0.787 (95 % CI
0.717-0.857), optimal cut-off = 45.9 mg/L for CRP (Fig. 3)
and 0.655 (95 % CI 0.570-0.739), optimal cut-off = 0.13 μg/
L for PCT (Fig. 4).
Sensitivity analyses for the combination of CRP and
PCT, using these optimal cut-offs, resulted in a PPV of
0.74 and a NPV of 0.58. Use of the other PCT cut-offs
did not result in better PPV or NPV (Table 2).
Impact of exclusion of patients with extra-pulmonary
infections from the excluded CAP group
The exclusion of the 12 patients with extra-pulmonary
bacterial infections from the 71 excluded CAP patients
led to a non statistically significant decrease of the me-
dian CRP values [17.3 mg/L (3.6-57.5) (p = 0.203)] and
PCT values [0.09 μg/L (0.06-0.27) (p = 0.309)] of the 59
remaining excluded CAP patients (see Additional file 3);
the AUC also increased to 0.851 (95 % CI 0.790-0.913)
for CRP and to 0.718 (95 % CI 0.636-0.799) for PCT,
without bettering predictive performances for CAP (see
Additional file 4). In the multivariate analysis, the pres-
ence of fever [OR 3.15 (1.29-7.73), p = 0.012] and the
increase in CRP level [odds ratio (OR) 1.02 (1.01-1.03),
p <0.001, for each mg] were independently associated
with definite CAP whereas PCT increase was not
(Table 3). The C-index of the final model was 0.862(95 % CI 0.802-0.921) and the Hosmer Lemeshow p
value was 0.002.
Impact of multiplex PCR results on biomarkers’ accuracy
Naso-pharyngeal multiplex PCR detected a microorgan-
ism in 61 of the 200 patients (30.5 %), including 33 out of
the 98 definite CAP (see Additional file 2). Among these
latter 33 patients, intracellular bacteria were identified in 4
(Mycoplasma pneumoniae in all), respiratory virus and
bacteria in 4 (Streptococcus pneumoniae + Influenza A
virus (1), Streptococcus pneumoniae + Rhinovirus (1),
Enterobacterieaceae + Rhinovirus (1), Intracellular bac-
teria + Influenza A virus (1)), and respiratory virus alone
in 25 (Influenza A virus (8), Influenza B virus (2), Para-
influenza virus (3), Coronavirus (2), Rhinovirus (2), re-
spiratory syncytial virus A (2), respiratory syncytial virus B
(2), Metapneumovirus (2), Adenovirus (1), Coronavirus +
Metapneumovirus (1)). For the 25 patients with viral CAP,
the median CRP value was 124.7 mg/L (68.9-223.0), and
median PCT value was 0.46 μg/L (0.18-1.97). In definite
CAP patients, the exclusion of these 25 patients with viral
CAP led to a non statistically significant increase of the
median CRP value 125.5 mg/L (63.3-209.5) (p = 0.93)
but an unexpected decrease of the median PCT value
0.21 μg/L (0.09-1.33) (p = 0.49) of the 73 remaining
definite CAP patients, and an AUC decrease to 0.847
(95 % CI 0.781-0.913) for CRP and to 0.687 (95 % CI
0.597-0.777) for PCT.
Discussion
The present study is novel as patients prospectively
benefited from extensive investigation to determine the
diagnosis of CAP in the ED, including both early multide-
tector thoracic CT-scan and day-28 adjudication commit-
tee. This led to the correction of CAP diagnosis previously
based on chest X-ray in a high number of patients. In
these extensively characterized patients, both CRP and
PCT lacked operational precision to allow the decision-
making process to rule out or confirm diagnosis of CAP
even in selected subgroups.
The clinical characteristics of the patients included in
this sub-study are consistent with those in the current
literature. As previously reported, patients frequently
had a history of respiratory disorders, cancer and
congestive heart failure [21, 22]. The design of the
ESCAPED study required exclusion of patients within
the highest CRB 65 categories, which limited the inclu-
sion of patients older than 65. This may explain why the
mean age of our patients (64 years) falls within the lower
values of those reported elsewhere [19]. Data to identify
the microbial agent responsible for the disease were col-
lected by the usual techniques and multiplex PCR. Viral
identification using naso-pharyngeal PCR that revealed
viral respiratory infection in approximately one-third of
Fig. 2 C-reactive protein (CRP) (upper panel) and procalcitonin (PCT) (lower panel) boxplot for patients according to each level of community-acquired
pneumonia diagnosis certainty classification. PCT values greater than 5 μg/L are not shown
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[23]. Therefore, we believe that our results can be extrapo-
lated to most emergency patients suffering from CAP.In the present study, patients were recruited on the
basis of initial clinical assessment for the diagnosis of
CAP. Therefore, we believe that the characteristics of
Table 2 Sensitivity, specificity, PPV and NPV according to different C-reactive protein (CRP) and procalcitonin (PCT) cut offs in the
patients with excluded or definite community acquired pneumonia
Biomarkers' cut-off Total Excluded CAP Definite CAP p value Se Sp PPV NPV LR+ AUC
(N = 169) (N = 71) (N = 98)
n (%) n (%) n (%)
CRP cut-off
> 20 mg/L 133 (79) 41 (58) 92 (94) <0.001 93.9 42.2 69.2 83.3 1.62
> 30 mg/L 123 (73) 35 (49) 88 (90) <0.001 89.8 50.7 71.5 78.2 1.82
> 50 mg/L 109 (64) 26 (37) 83 (85) <0.001 84.7 63.4 76.1 75.0 2 .31 0.787
> 70 mg/L 92 (54) 24 (34) 68 (69) <0.001 69.4 66.2 73.9 61.0 2.05
> 100 mg/L 73 (43) 15 (21) 58 (59) <0.001 59.2 78.9 79.4 58.3 2.80
PCT cut-off
> 0.10 μg/L 115 (68) 39 (55) 76 (78) 0.003 77.5 45.1 66.1 59.2 1.41
> 0.25 μg/L 74 (44) 25 (35) 49 (50) 0.061 50.0 64.7 66.2 48.4 1.41 0.655
> 0.50 μg/L 53 (31) 16 (23) 37 (38) 0.044 37.7 77.5 69.8 47.4 1.67
CRP >49.5 mg/L and PCT cut-off combined
PCT > 0.13 μg/L 83 (49) 21 (29) 62 (63) <0.001 63.2 70.4 74.6 58.1 2.13
PCT > 0.1 μg/L 90 (53) 22 (31) 68 (69) <0.001 69.4 69.0 75.5 62.0 2.23
PCT > 0.25 μg/L 68 (40) 21 (29) 47 (48) 0.018 47.9 70.4 69.1 49.5 1.62
PCT > 0.5 μg/L 51 (30) 15 (21) 36 (36) 0.041 36.7 78.9 70.6 47.4 1.74
Abbreviations: CAP community acquired pneumonia, Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, LR likelihood ratio,
AUC area under the curve
Fig. 3 C-reactive protein ROC curves predicting definite community-acquired pneumonia diagnosis. AUC = 0.787. 95 % CI = 0.717 to 0.857. Youden’s
index = 0.501 for an optimal CRP cut-off point at 45.9 mg/L ROC receiver operating characteristic, AUC area under the curve, CI confidence interval, CRP
C-reactive protein
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Fig. 4 Procalcitonin ROC curve predicting definite community-acquired pneumonia diagnosis. AUC = 0.655. 95 % CI = 0.570 to 0.739. Youden’s
index = 0.307 for an optimal PCT cut-off point at 0.13 μg/L ROC receiver operative characteristic, AUC area under the curve, CI confidence interval,
PCT procalcitonin
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tioners to consider a possible diagnosis of CAP. In these
patients, the design of our study allowed us to confirm or
refute CAP diagnosis with a high level of certainty. Results
confirmed the poor predictive value of clinical symptoms
(new onset of systemic features and symptoms of an acute
lower respiratory tract illness) in identifying CAP patients
[21]. Indeed, clinical presentation of excluded CAP pa-
tients was similar to that of definite CAP patients except
for fever and cough that were more frequent in definite
CAP patients. Furthermore, the design also revealed that
the combination of clinical symptoms and chest X-ray
results led to CAP misdiagnosis in a high number of
patients, including the 98 whose CAP diagnosis was
excluded by the adjudication committee and who would
have been considered as possible, probable or definite
CAP without the use of the CT scan. This low specificity
of clinical-standard radiological evaluation led to the con-
sideration of either non-infectious pulmonary diseases
(such as, cardiac failure, pulmonary embolism, pulmonary
neoplasia or bronchitis) or extra-pulmonary infectious
diseases as CAP. Of note, some of these diseases are also
associated with increased biomarker values. This raises
concerns about previous evaluations of biomarkers inCAP-suspected patients, which used clinical and standard
radiological (chest X-ray) evaluations as the gold standard
for CAP diagnosis [15].
The use of biomarkers has been advocated to improve
diagnosis and management of patients with lower re-
spiratory tract infections [14]. However, this issue is still
unresolved [24], with conflicting positions [14, 15, 25, 26].
In our study, while median values of both biomarkers did
increase with level of certainty for CAP diagnosis, we were
unable to establish discriminating values for PCT. Recent
data suggested that CRP could be of more help in assisting
in the diagnosis of lower respiratory tract infections
(LRTI) [15, 27, 28]. In our study, although CRP seems
more discriminating than PCT, neither the experimental
exclusion of extra-pulmonary bacterial infections from the
excluded CAP group, nor the exclusion of viral CAP from
the definite CAP patients group, made possible the deter-
mination of a discriminant cutoff. The combination of
CRP and PCT was not more discriminating than each
biomarker separately. An operational algorithm has been
released to assist physicians in prescribing antimicrobial
therapy [14, 26, 29]. According to this strategy, a PCT
concentration higher than 0.25 μg/L should prompt
administration of antibiotics to patients with suspected
Table 3 Univariate and multivariate analysis of the clinical characteristics of excluded CAP patients without extra-pulmonary
infections compared to definite CAP patients
Patient characteristics n (%) or
median IQR
Total Excluded CAPa Definite CAP p OR p
N = 157 N = 59 N = 98 [95 % CI]
Cough 122 (77.7) 41 (69.5) 81 (82.7) 0.047 -
Chest pain 53 (33.7) 16 (27.1) 37 (37.8) 0.168 -
Expectoration 78 (49.7) 27 (45.8) 51 (52.0) 0.509 -
Dyspnea 111 (70.7) 44 (74.6) 67 (68.4) 0.471 -
Chills 52 (33.1) 21 (35.6) 31 (31.6) 0.727 -
Headaches 33 (21.0) 9 (15.2) 24 (24.5) 0.225 -
Myalgia 35 (22.3) 11 (18.6) 24 (24.5) 0.432 -
Crackles 49 (31.2) 13 (22.0) 36 (36.7) 0.051 -
Fever 51 (32.5) 10 (16.9) 41 (41.8)) 0.001 3.15 [1.29-7.73] 0.012
Confusion 0 0 0 - -
Respiratory rate > 30/min 19 (12.1) 7 (11.9) 12 () 0.856 -
Heart rate > 125/min 11 (7.0) 2 (3.4) 9 (9.2) 0.211 -
Systolic blood pressure < 90 mmHg 3 (1.9) 0 3 (3.1) 0.292 -
Diastolic blood pressure < 60 mmHg 10 (6.4) 1 () 9 (9.2) 0.091 -
White blood cells > 10.103 /mm3 86 (54.8) 22 (37.3) 64 (65.3) 0.004 -
PaO2 < 60 mmHg or Sat02 < 90 % 18 (11.4) 6 (10.1) 12 (12.2) 0.799 -
CRP 74 [21.3 – 146.1] 17.3 [3.6 – 57.5] 125.1 [65.0 - 208.7] <0.001 1.02 [1.01-1.03] <0.001
PCT 0.17 [0.07 – 0.72] 0.09 [0.06 - 0.28] 0.24 [0.11 - 1.38] <0.001 - -
CAP community-acquired pneumonia, CRP C-reactive protein, PCT procalcitonin
aPatients with excluded CAP without extra-pulmonary infections
The bold data correspond to the variables included into the multivariate logistic regression
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performance. Additionally, mean PCT levels remained
above this threshold both in excluded CAP patients
without infectious disorders and in definite CAP pre-
sumably related to virus. Therefore, the gold standard
for the diagnosis of CAP may influence the perform-
ance and utility of PCT in this setting.
This study has some limitations. First, the adjudication
committee was not blinded to the value of biomarkers
measured at bedside in some patients (70 for CRP and
131 for PCT) and its CAP classification could thus have
been influenced by these results. However, the lack of
statistically significant differences in the mean CRP and
PCT values in the definite CAP cases, whether or not
these biomarkers were available for the adjudication
committee, argues against a major impact of these
results on adjudication committee classification. Second,
another critical point is the prescription of antibiotic
therapy (34 %) previous to inclusion. We cannot exclude
that these previously-treated CAP patients may have
altered biomarker performance and reduced the yield of
bacterial cultures, although such a population reflects
the usual emergency department practice. Third, multi-
plex PCR was performed on naso-pharyngeal sampling
and not on lower respiratory tract samples, which doesnot allow definite confirmation of the viral origin of
CAP. However, a recent large study on CAP patients
which reported a viral etiology of CAP at a comparable
rate, did not find upper respiratory tract shedding in a
control population without CAP explored during the
same year and season [30]. Finally, even if multidetector
thoracic CT scan is a better imaging examination
than X-ray to explore the chest, only invasive local
microbiological samples would have provided a diagnosis
with certainty.
Conclusions
Given the diversity of the clinical and radiological CAP
presentations, CAP diagnosis is often uncertain. In our
population of patients treated in the emergency room
with clinical symptoms evoking CAP, neither CRP nor
PCT cut-off values carried sufficient weight to confirm
or refute CAP diagnosis at bedside; this underlines that
these biomarkers are telltales of the host inflammatory
response to the intrusion of microorganisms independ-
ent of the site of infection. These results, based on a sys-
tematic thoracic CT scan evaluation of CAP-suspected
patients, do not argue for the use of CRP and PCT in
routine care to diagnose CAP with certainty in patients
visiting the ED for suspected CAP.
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 The predictive value of clinical symptoms in
identifying CAP patients is poor
 No CRP or PCT cut-off value is sufficiently
discriminating to confirm or refute CAP diagnosis
with a high level of certainty
 The diagnostic accuracy of biomarkers was not
improved when CAP cases considered as viral were
excluded from analysis.
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